Show simple item record

dc.contributor.authorDe Campos, E S
dc.contributor.authorRadford, John A
dc.contributor.authorSteward, William P
dc.contributor.authorMilroy, Robert
dc.contributor.authorDougal, Mark
dc.contributor.authorSwindell, Ric
dc.contributor.authorTesta, Nydia G
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-05-19T10:57:24Z
dc.date.available2010-05-19T10:57:24Z
dc.date.issued1995-07
dc.identifier.citationClinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. 1995, 13 (7):1623-31 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid7602351
dc.identifier.urihttp://hdl.handle.net/10541/99246
dc.description.abstractPURPOSE: Recombinant human erythropoietin (r-Hu-EPO) is known to be effective in untreated cancer patients. Here we assess the possibility that r-Hu-EPO may also prevent or reduce anemia in patients who receive cytotoxic chemotherapy. METHODS: Thirty-six patients with small-cell lung carcinoma (SCLC) were enrolled onto a three-arm, randomized trial to investigate the effect of r-Hu-EPO on hemoglobin (Hb) levels and RBC and platelet (Plt) transfusions during chemotherapy. Bone marrow progenitors were studied before and after treatment. Two groups of patients received r-Hu-EPO at a dose of either 150 IU/kg (group 150) or 300 IU/kg (group 300) three times per week for the duration of chemotherapy. A control group did not receive r-Hu-EPO (group O). A maximum of six cycles of a chemotherapy regimen that consisted of vincristine, ifosfamide, carboplatin, and etoposide (VICE) were given to all patients. Hematologic parameters were measured weekly, and RBC or Plt transfusions were given for Hb levels less than 9 g/dL and Plt counts less than 20 x 10(9)/L. RESULTS: Hb levels decreased in all patients, but onset of anemia was delayed in groups that received r-Hu-EPO (P = .002). A total of 116 U RBC were transfused in group 0, 54 in group 150, and 52 in group 300 (P = .017). In addition, there was a nonsignificant trend toward higher Plt counts and fewer Plt transfusions in patients who received r-Hu-EPO. CONCLUSION: r-Hu-EPO at a dose of either 150 or 300 IU/kg three times weekly delays the onset of anemia and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC. A possible effect of r-Hu-EPO on platelet numbers deserves further study.
dc.language.isoenen
dc.subjectAnaemiaen
dc.subjectHaemoglobin Aen
dc.subjectLung Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAnemia
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshColony-Forming Units Assay
dc.subject.meshDrug Administration Schedule
dc.subject.meshErythrocyte Transfusion
dc.subject.meshErythropoietin
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshGranulocytes
dc.subject.meshHemoglobin A
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshIron
dc.subject.meshLeukocyte Count
dc.subject.meshLung Neoplasms
dc.subject.meshMacrophages
dc.subject.meshMale
dc.subject.meshMesna
dc.subject.meshMiddle Aged
dc.subject.meshPlatelet Count
dc.subject.meshPlatelet Transfusion
dc.subject.meshRecombinant Proteins
dc.subject.meshVincristine
dc.titleClinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: Recombinant human erythropoietin (r-Hu-EPO) is known to be effective in untreated cancer patients. Here we assess the possibility that r-Hu-EPO may also prevent or reduce anemia in patients who receive cytotoxic chemotherapy. METHODS: Thirty-six patients with small-cell lung carcinoma (SCLC) were enrolled onto a three-arm, randomized trial to investigate the effect of r-Hu-EPO on hemoglobin (Hb) levels and RBC and platelet (Plt) transfusions during chemotherapy. Bone marrow progenitors were studied before and after treatment. Two groups of patients received r-Hu-EPO at a dose of either 150 IU/kg (group 150) or 300 IU/kg (group 300) three times per week for the duration of chemotherapy. A control group did not receive r-Hu-EPO (group O). A maximum of six cycles of a chemotherapy regimen that consisted of vincristine, ifosfamide, carboplatin, and etoposide (VICE) were given to all patients. Hematologic parameters were measured weekly, and RBC or Plt transfusions were given for Hb levels less than 9 g/dL and Plt counts less than 20 x 10(9)/L. RESULTS: Hb levels decreased in all patients, but onset of anemia was delayed in groups that received r-Hu-EPO (P = .002). A total of 116 U RBC were transfused in group 0, 54 in group 150, and 52 in group 300 (P = .017). In addition, there was a nonsignificant trend toward higher Plt counts and fewer Plt transfusions in patients who received r-Hu-EPO. CONCLUSION: r-Hu-EPO at a dose of either 150 or 300 IU/kg three times weekly delays the onset of anemia and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC. A possible effect of r-Hu-EPO on platelet numbers deserves further study.


This item appears in the following Collection(s)

Show simple item record